Protagonist Therapeutics PTGX Business Segments — Investment Income Interest
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's business segments — investment income interest.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's business segments — investment income interest?
- Protagonist Therapeutics (PTGX) reported business segments — investment income interest of $5.88M in Q1 2026.
- How has Protagonist Therapeutics's business segments — investment income interest changed year-over-year?
- Protagonist Therapeutics's business segments — investment income interest decreased by 22.4% year-over-year, from $7.57M to $5.88M.
- What is the long-term trend for Protagonist Therapeutics's business segments — investment income interest?
- Over 3 years (2022 to 2025), Protagonist Therapeutics's business segments — investment income interest has grown at a 92.1% compound annual growth rate (CAGR), from $4.06M to $28.79M.
- What does business segments — investment income interest mean?
- This represents the interest income generated from the company's cash, cash equivalents, and marketable securities. For clinical-stage companies, this is a vital source of non-dilutive capital that helps offset operating expenses. It reflects the company's treasury management strategy and the yield on its liquid assets.